0.10Open0.10Pre Close0 Volume415 Open Interest2.50Strike Price0.00Turnover2070.08%IV604.61%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier3DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type0.4395Delta0.5906Gamma3.69Leverage Ratio-0.0493Theta0.0000Rho1.62Eff Leverage0.0001Vega
Organovo Holdings Stock Discussion
📊⚡️📊
$Applied Therapeutics (APLT.US)$ Crashed after FDA CRL but will resubmit. Dropped from 10 to 1.3 rebounded to 1.95. SI 16%
$PainReform (PRFX.US)$ Microfloat. Up after hours. SI 20%. 0 shares LTB. CTB 436%. If there is no catalyst, microfloats will be a quick play.✔️
$Blue Ocean Acquisition Corp(Delisted) (BOCN.US)$ Merger ...
Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting
Organovo Holdings (NASDAQ:ONVO)presented Phase 2 clinical trial results for FXR314 at The Liver Meeting. The study involved 214 MASH patients randomized to receive 3mg, 6mg FXR314, or placebo. The drug demonstrated statistically significant liver fat reduction from baseline: 22.8% (3mg) and 17.5% (6mg) versus 6.1% placebo. Notably, >30% MRI-PDFF reduction was ac...
Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases
Organovo Holdings (Nasdaq: ONVO) announces that its lead clinical stage drug, FXR314, will be featured in an oral presentation at The Liver Meeting, sponsored by the American Association for the Study of Liver Diseases (AASLD). The presentation, scheduled for November 17, 2024, will be del...
Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis
Organovo Holdings (Nasdaq: ONVO) presented its outlook and plans at the Jones Trading Healthcare Conference, focusing on FXR314, its treatment for inflammatory bowel disease (IBD). Executive Chairman Keith Murphy highlighted the strong preclinical and human rationale for FXR314 in Phase 2a ulcerative colitis...
NEWS
Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering
In a significant step forward for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH), Organovo Holdings Inc. has announced positive Phase 2 trial results for its experimental drug, FXR314. This development marks a pivotal moment in the fight against MASH, a severe form of fatty liver disease that poses a su...
$Organovo Holdings (ONVO.US)$ huge opportunity 💯💯🔥💯🏆🏆🆙🆙💴🆙🏆🏆💯💯🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥
$Organovo Holdings (ONVO.US)$ buy💯💯🔥💯🏆🏆💴🆙🆙🆙🆙
No comment yet